Lateral Pharma Secures U.S. Composition‑of‑Matter Patent for LAT9997 in Neuropathic Pain

Lateral Pharma Secures U.S. Composition of Matter Patent for LAT9997 in Neuropathic Pain   Lateral Pharma (LP) is pleased to announce LAT9997, our next‑generation therapeutic candidate targeting the LanCL pathway, was granted a composition‑of‑matter patent by the United States Patent and Trademark Office (USPTO) for use in treating neuropathic pain. LAT9997 represents an optimised evolution…